What does “bioidentical hormone therapy” actually mean?
“Bioidentical” means that the hormone molecule is chemically identical to a hormone made by the human body. Estradiol is bioidentical to human estradiol. Micronized progesterone is bioidentical to human progesterone.
The important point is that bioidentical does not mean compounded, alternative or automatically safer. Regulated prescription products can be bioidentical too. The term has become confusing because some clinics use “BHRT” mainly to market custom-compounded creams, capsules or hormone pellets.
Is BHRT the same thing as menopause hormone therapy?
Not exactly. Menopause hormone therapy (MHT or HRT) is the broad medical category. It includes different estrogens and progestogens delivered by tablets, patches, gels, sprays, vaginal products and other routes.
A regimen using estradiol and micronized progesterone is both conventional menopause hormone therapy and bioidentical hormone therapy. A custom-compounded mixture containing estradiol, estriol, progesterone, testosterone or DHEA is also often called BHRT, but it has a different evidence and quality-control profile.
Which hormones are commonly used?
- Estradiol is the main estrogen used to treat hot flushes, night sweats and other estrogen-deficiency symptoms.
- Progesterone is usually added when a woman with a uterus uses systemic estrogen, because it protects the endometrium from excessive estrogen stimulation.
- Testosterone may be considered in selected women with distressing hypoactive sexual desire disorder (HSDD). Evidence does not support using it as a general treatment for low energy, brain fog, weight gain or “anti-aging.”
- DHEA has specific uses, including regulated vaginal preparations in some countries for genitourinary symptoms. Systemic DHEA is not equivalent to standard menopause hormone therapy.
Pregnenolone, estriol-heavy mixtures and multi-hormone “optimization” protocols are also marketed, but the evidence behind them is much less consistent.
What symptoms can hormone therapy genuinely help?
Systemic menopause hormone therapy is the most effective treatment for troublesome vasomotor symptoms such as hot flushes and night sweats. It can also improve sleep when poor sleep is being driven by night sweats, and it helps prevent bone loss while treatment continues.
For vaginal dryness, burning, painful sex or recurrent urinary symptoms related to genitourinary syndrome of menopause (GSM), low-dose local vaginal estrogen can be highly effective and exposes the rest of the body to far less estrogen than systemic therapy.
Mood, concentration, joint symptoms and sexual wellbeing may improve in some women, but these symptoms have many possible causes. Hormone therapy should not become an automatic explanation for every problem that appears in midlife.
How does hormone therapy work in simple terms?
During perimenopause and menopause, ovarian hormone production becomes irregular and eventually much lower. Hormone therapy supplies some of the missing hormone signal.
Estrogen acts in the brain, blood vessels, bone, skin and genitourinary tissues. Replacing it can reduce the unstable temperature regulation that contributes to hot flushes and can improve estrogen-dependent tissues. Progesterone does a different job: when systemic estrogen stimulates the lining of the uterus, adequate progestogen exposure helps prevent that lining from becoming abnormally thick.
Why do I need progesterone if I still have a uterus?
Systemic estrogen used on its own can stimulate the endometrium and increase the risk of endometrial hyperplasia and cancer. If you have a uterus, a suitable progestogen is therefore usually part of systemic estrogen therapy.
After hysterectomy, estrogen can often be used without progesterone, although individual circumstances vary. Vaginal low-dose estrogen for GSM is different: many low-dose local regimens do not require routine progesterone because systemic exposure is very low.
Does the route of estrogen matter?
Yes. Tablets and transdermal products reach the body differently.
Oral estrogen passes through the liver first and has stronger effects on clotting proteins and some metabolic markers. Transdermal estradiol — patches, gels or sprays — avoids much of that first-pass liver effect and is generally favored when venous-thromboembolism or cardiometabolic risk is a concern.
This does not mean a patch has zero risk or that tablets are “bad.” Route, dose, age, time since menopause and personal medical history all change the risk-benefit balance.
Are compounded bioidentical hormones better than regulated products?
There is no good evidence that custom-compounded bioidentical hormones are inherently safer or more effective than regulated hormone medicines. ACOG and other professional bodies recommend regulated products when an appropriate formulation exists.
Compounding can be useful when a patient genuinely needs a formulation or ingredient combination that is not commercially available. But routine claims that compounded BHRT is “more natural,” safer, individually precise or free of standard hormone-therapy risks are not supported by strong evidence.
Compounded preparations can also vary in potency, absorption and consistency. That matters when the treatment is affecting the endometrium, blood vessels, breast tissue and androgen-sensitive tissues.
Are hormone pellets better because they release hormones continuously?
Pellets are small implants placed under the skin that release hormone over months. The convenience is real: there is no daily tablet, gel or patch to remember.
The trade-off is control. Once a pellet has been inserted, the dose cannot be quickly reduced or stopped if the level is too high or side effects appear. Published pellet studies and reviews report potential problems including supraphysiologic hormone levels, bleeding, acne, increased facial hair and difficulty adjusting treatment between insertions.
Recent reviews continue to call for better long-term comparative evidence. Pellets may have a role in selected patients, but “long-lasting” should not be confused with “better studied.”
What does the evidence say about testosterone for women?
The clearest evidence-based indication is hypoactive sexual desire disorder (HSDD) in appropriately assessed postmenopausal women. The benefit is usually moderate, not a transformation into a younger hormonal state.
Current evidence does not support testosterone as a routine treatment for fatigue, cognition, bone health, weight loss or general wellness. Guidelines generally favor carefully dosed transdermal treatment when testosterone is used, with monitoring to avoid levels above the normal female physiological range.
Acne, increased facial or body hair and scalp hair loss can occur when androgen exposure is excessive. Voice deepening and clitoral enlargement are uncommon but potentially irreversible androgenic effects and are reasons to avoid supraphysiologic dosing.
Can BHRT help me lose weight or reverse aging?
Hormone therapy is not a weight-loss treatment and should not be sold as one. Menopause can change body composition, sleep and activity, and treating severe symptoms may make it easier to exercise and sleep well. That is different from directly causing substantial fat loss.
Claims that BHRT prevents dementia, heart attacks, diabetes or aging in otherwise healthy people go beyond the evidence. Menopause hormone therapy is prescribed primarily for symptom relief and, in selected women, bone protection — not as a longevity drug.
Is hormone therapy good or bad for the heart?
Neither statement is accurate on its own. Timing and formulation matter.
Current reviews suggest that for many healthy symptomatic women who start treatment before age 60 or within about 10 years of menopause, the overall benefit-risk balance can be favorable. Starting systemic hormone therapy later, or in women with established cardiovascular or thrombotic disease, requires more caution.
Hormone therapy should not be started specifically to prevent cardiovascular disease. Transdermal estradiol generally has a more favorable clotting profile than oral estrogen.
What about breast-cancer risk?
Breast-cancer risk depends on the hormones used, duration, baseline risk and whether estrogen is combined with a progestogen. It cannot be reduced to one percentage that applies to everyone.
Large evidence reviews continue to find that combined systemic estrogen-progestogen therapy is associated with more breast-cancer risk than estrogen-only therapy, particularly with longer use. Different progestogens may not have identical risk profiles, but “micronized progesterone is bioidentical” does not mean the whole regimen is risk-free.
Personal or strong family history of breast cancer needs individualized assessment. Systemic hormone therapy is generally avoided after hormone-sensitive breast cancer unless a specialist team considers exceptional circumstances.
Do saliva tests tell me the exact hormone dose I need?
Usually no. Salivary sex-hormone levels vary and have not been shown to provide a reliable basis for custom-dosing menopause hormone therapy. Symptoms, medical history, bleeding pattern, treatment response and safety monitoring are more important.
Blood tests can be useful in specific situations — for example, assessing suspected premature ovarian insufficiency, checking testosterone exposure, or investigating unexpected symptoms — but routine treatment is not simply a matter of chasing a single “optimal” hormone number.
Who may not be a good candidate for systemic hormone therapy?
Systemic treatment may be unsuitable, or may require specialist review, in people with certain histories such as unexplained vaginal bleeding, estrogen-sensitive cancer, previous venous thromboembolism, stroke or heart attack, significant liver disease, or a high baseline thrombotic or cardiovascular risk.
The answer is not always a simple yes or no. Route and formulation can matter, and low-dose local vaginal estrogen has a very different systemic exposure profile from full systemic therapy.
How quickly should I know if treatment is helping?
Hot flushes and night sweats often begin to improve within weeks, although dose and formulation may need adjustment. Vaginal and urinary symptoms may take several weeks of consistent local treatment. Bone protection is a long-term effect rather than something you feel.
If treatment produces no meaningful benefit after a reasonable trial, or causes persistent side effects, the plan should be reassessed rather than endlessly adding more hormones.
What should a sensible BHRT consultation look like?
A good consultation starts with the symptom and the medical history, not with a predetermined “hormone optimization” package. You should understand:
- which symptom each hormone is intended to treat;
- whether the product is regulated or custom compounded;
- why a particular route was chosen;
- whether endometrial protection is adequate if you have a uterus;
- what side effects and warning symptoms to watch for;
- how and when the treatment will be reviewed.
Bioidentical hormones are not fake medicine. Estradiol and micronized progesterone are well-established medical therapies. The problem begins when the word “bioidentical” is used to imply that any compounded mixture or pellet is automatically safer, more natural or more scientific than standard hormone therapy.
